A Phase 4, Randomized, Double-blind Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine in Adults 50 Years and Older Who Received 1 Or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine Prior to Study Enrollment.

Trial Profile

A Phase 4, Randomized, Double-blind Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine in Adults 50 Years and Older Who Received 1 Or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine Prior to Study Enrollment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections; Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 23 May 2016 Primary endpoints and their time frame (for AE it changed from 6 months to 28-42 days) revised.
    • 05 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 03 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 May 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top